AAV FXN Vector With Truncated 3' UTR for Friedreich's Ataxia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no approved cure for Friedreich's ataxia, a genetic disease caused by a mutation in the FXN gene leading to reduced expression of the mitochondrial protein frataxin, resulting in neurological and cardiac degeneration with no FDA-approved treatment.
Innovation Solution
A recombinant adeno-associated virus (rAAV) vector containing a codon-optimized human FXN gene with a truncated 3' UTR, operably linked to a promoter, is delivered to cardiomyocytes derived from induced pluripotent stem cells to increase mitochondrial activity and frataxin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a full-length FXN gene with complete 3' UTR is used in the AAV vector, then the gene expression regulation is maintained, but the vector size increases and packaging efficiency decreases
Solution Approach 1:
The patent extracts and removes the complete 3' UTR from the FXN gene, retaining only the essential coding sequence and a truncated portion of the 3' UTR. This extraction eliminates unnecessary nucleotides that do not contribute to gene regulation, thereby reducing the overall vector size while preserving the functional elements needed for proper gene expression and protein translation.
Solution Approach 2:
The patent applies local quality by selectively preserving only the critical regions of the FXN gene (coding sequence and essential regulatory elements) while truncating the non-essential 3' UTR. This approach maintains the local functional quality needed for gene expression in the essential regions while removing excess material that increases vector size without providing proportional benefit.
2Stability of the object's composition
If the FXN gene is not codon-optimized, then the native gene sequence is preserved, but the expression level in human cells is reduced
Solution Approach 1:
The patent applies parameter changes by modifying the codon composition of the FXN gene to optimize it for human cell translation machinery. Specific codons are changed to those preferred by human cells, increasing the efficiency of protein synthesis while maintaining the exact amino acid sequence. This parameter optimization directly increases expression levels and productivity in human cell targets.
3Adaptability or versatility
If the AAV vector targets multiple affected organs, then the therapeutic coverage is improved, but the vector design complexity increases
Solution Approach 1:
The patent applies universality by designing a single AAV vector construct that can target multiple affected organs (heart, brain, pancreas, skeletal muscle) simultaneously. The truncated FXN gene expression cassette is designed to be broadly applicable across different tissue types, allowing one vector to serve multiple therapeutic functions and address the multisystem nature of Friedreich's ataxia without requiring separate vectors for each organ.
Data Source
AI summary
Provided herein are nucleic acids, recombinant adeno-associated viral particles, compositions and methods related to treating Friedreich's ataxia. In some examples, the nucleic acids, recombinant adeno-associated viral particles, compositions and methods involve use of a FXN coding sequence, a truncated FXN 3′ UTR, and a promoter.